ArticleBMC cardiovascular disorders2026

Comparative effectiveness and safety of inclisiran versus evolocumab and alirocumab: a 180-day real-world study.

Jiafang Yao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.